PHARMACOPEIA INC
10-Q, EX-27.1, 2000-08-14
COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH
Previous: PHARMACOPEIA INC, 10-Q, EX-10.54, 2000-08-14
Next: INSIGNIA SOLUTIONS PLC, 10-Q, 2000-08-14



<TABLE> <S> <C>

<PAGE>
<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE
FINANCIAL STATEMENTS FOR THE SIX MONTHS ENDED JUNE 30, 2000 AND IS QUALIFIED IN
ITS ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS.
</LEGEND>
<MULTIPLIER> 1,000

<S>                             <C>
<PERIOD-TYPE>                   6-MOS
<FISCAL-YEAR-END>                          DEC-31-2000
<PERIOD-START>                             JAN-01-2000
<PERIOD-END>                               JUN-30-2000
<CASH>                                          65,568
<SECURITIES>                                   112,803
<RECEIVABLES>                                   19,738
<ALLOWANCES>                                     (642)
<INVENTORY>                                          0
<CURRENT-ASSETS>                               201,234
<PP&E>                                          32,766
<DEPRECIATION>                                (21,883)
<TOTAL-ASSETS>                                 242,924
<CURRENT-LIABILITIES>                           39,353
<BONDS>                                              0
                                0
                                          0
<COMMON>                                             2
<OTHER-SE>                                     198,461
<TOTAL-LIABILITY-AND-EQUITY>                   242,924
<SALES>                                          2,728
<TOTAL-REVENUES>                                51,741
<CGS>                                            2,429
<TOTAL-COSTS>                                   18,515
<OTHER-EXPENSES>                                39,298
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                   0
<INCOME-PRETAX>                                (2,210)
<INCOME-TAX>                                     (519)
<INCOME-CONTINUING>                            (2,729)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                   (2,729)
<EPS-BASIC>                                      (.12)
<EPS-DILUTED>                                    (.12)


</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission